284461-74-1 Usage
Description
Sorafenib related compound 12, also known as N-Desmethyl Sorafenib, is a metabolite of Sorafenib (S676850) derived from hydrolyzable tannins found in various plant sources. It possesses anti-proliferative properties and is a promising pharmaceutical candidate for various applications.
Used in Pharmaceutical Industry:
Sorafenib related compound 12 is used as an anti-proliferative agent for its ability to inhibit the growth of human breast cancer cells. It modulates several oncological signaling pathways, exerting inhibitory effects on tumor growth and progression.
Used in Drug Development:
Sorafenib related compound 12 is used as a potential candidate for the development of novel therapeutic agents, particularly against solid malignancies. Its anti-proliferative activity makes it a valuable compound for further research and development in the field of oncology.
Used in Cancer Research:
Sorafenib related compound 12 is used as a research tool for studying the mechanisms of action and potential synergistic effects when combined with conventional chemotherapeutic drugs. This can help enhance chemo-sensitivity and efficacy in resistant cases, leading to improved treatment options for cancer patients.
Check Digit Verification of cas no
The CAS Registry Mumber 284461-74-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,4,4,6 and 1 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 284461-74:
(8*2)+(7*8)+(6*4)+(5*4)+(4*6)+(3*1)+(2*7)+(1*4)=161
161 % 10 = 1
So 284461-74-1 is a valid CAS Registry Number.
284461-74-1Relevant articles and documents
ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
-
, (2016/02/12)
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
RAF KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY
-
Page/Page column 29, (2008/12/08)
The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
DIARYL UREAS AND COMBINATIONS
-
Page/Page column 45-46, (2008/06/13)
The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I) : B-NH-C(O)-NH-L-M-L1-(Q)1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. Each Q is independently C(O)R4, C(O)OR4 and C(O)NR4R5; and L' is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.
